These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

161 related items for PubMed ID: 3032611

  • 1. In vitro activity of LY146032 (daptomycin), a new peptolide.
    Ehlert F, Neu HC.
    Eur J Clin Microbiol; 1987 Feb; 6(1):84-90. PubMed ID: 3032611
    [Abstract] [Full Text] [Related]

  • 2. In vitro activity of LY146032 (daptomycin) against selected aerobic bacteria.
    Jorgensen JH, Maher LA, Redding JS.
    Eur J Clin Microbiol; 1987 Feb; 6(1):91-6. PubMed ID: 3032612
    [Abstract] [Full Text] [Related]

  • 3. In vitro activity of LY264826 compared to other glycopeptides and daptomycin.
    Chin NX, Neu HC.
    Diagn Microbiol Infect Dis; 1991 Feb; 14(2):181-4. PubMed ID: 1651826
    [Abstract] [Full Text] [Related]

  • 4. In vitro activity of the new glycopeptide decaplanin.
    Neu HC, Chin NX, Niu WW.
    Eur J Clin Microbiol Infect Dis; 1992 May; 11(5):458-62. PubMed ID: 1330562
    [Abstract] [Full Text] [Related]

  • 5. Comparative in vitro activity of LY146032 (daptomycin) against gram-positive cocci.
    Machka K, Braveny I.
    Eur J Clin Microbiol; 1987 Feb; 6(1):96-9. PubMed ID: 3032613
    [Abstract] [Full Text] [Related]

  • 6. Comparative in vitro activity of LY146032 (daptomycin), a new lipopeptide antimicrobial.
    Hodinka RL, Jack-Wait K, Wannamaker N, Walden TP, Gilligan PH.
    Eur J Clin Microbiol; 1987 Feb; 6(1):100-3. PubMed ID: 3032607
    [Abstract] [Full Text] [Related]

  • 7. In-vitro activity of LY146032 against Staphylococcus aureus, Listeria monocytogenes, Corynebacterium JK, and Bacillus spp., in comparison with various antibiotics.
    Van der Auwera P, Grenier P, Klastersky J.
    J Antimicrob Chemother; 1987 Aug; 20(2):209-12. PubMed ID: 2822648
    [Abstract] [Full Text] [Related]

  • 8. Activity of mersacidin, a novel peptide, compared with that of vancomycin, teicoplanin, and daptomycin.
    Niu WW, Neu HC.
    Antimicrob Agents Chemother; 1991 May; 35(5):998-1000. PubMed ID: 1649577
    [Abstract] [Full Text] [Related]

  • 9. Comparative in-vitro activity of LY146032 and eight other antibiotics against gram-positive bacteria isolated from children.
    Kline MW, Mason EO, Kaplan SL, Lamberth LB, Johnson GS.
    J Antimicrob Chemother; 1987 Aug; 20(2):203-7. PubMed ID: 2822647
    [Abstract] [Full Text] [Related]

  • 10. In-vitro susceptibility of gram-positive cocci to LY146032 teicoplanin, sodium fusidate, vancomycin, and rifampicin.
    Pohlod DJ, Saravolatz LD, Somerville MM.
    J Antimicrob Chemother; 1987 Aug; 20(2):197-202. PubMed ID: 2822646
    [Abstract] [Full Text] [Related]

  • 11. In vitro activity of LY146032 against staphylococci, streptococci, and enterococci.
    Fass RJ, Helsel VL.
    Antimicrob Agents Chemother; 1986 Nov; 30(5):781-4. PubMed ID: 3026240
    [Abstract] [Full Text] [Related]

  • 12. Comparative in-vitro activity of LY146032 a new peptolide, with vancomycin and eight other agents against gram-positive organisms.
    Benson CA, Beaudette F, Trenholm G.
    J Antimicrob Chemother; 1987 Aug; 20(2):191-6. PubMed ID: 2822645
    [Abstract] [Full Text] [Related]

  • 13. In-vitro activity of LY146032 against Staphylococcus aureus and S. epidermidis.
    Coudron PE, Johnston JL, Archer GL.
    J Antimicrob Chemother; 1987 Oct; 20(4):505-11. PubMed ID: 2824426
    [Abstract] [Full Text] [Related]

  • 14. Antimicrobial activity and spectrum of LY146032, a lipopeptide antibiotic, including susceptibility testing recommendations.
    Jones RN, Barry AL.
    Antimicrob Agents Chemother; 1987 Apr; 31(4):625-9. PubMed ID: 3038001
    [Abstract] [Full Text] [Related]

  • 15. LY146032: activity and resistance development in vitro.
    Mouton RP, Mulders SL.
    J Antimicrob Chemother; 1987 Oct; 20(4):513-7. PubMed ID: 2824427
    [Abstract] [Full Text] [Related]

  • 16. Activities of daptomycin and teicoplanin against Staphylococcus haemolyticus and Staphylococcus epidermidis, including evaluation of susceptibility testing recommendations.
    Low DE, McGeer A, Poon R.
    Antimicrob Agents Chemother; 1989 Apr; 33(4):585-8. PubMed ID: 2543286
    [Abstract] [Full Text] [Related]

  • 17. In vitro activities of two ketolides, HMR 3647 and HMR 3004, against gram-positive bacteria.
    Malathum K, Coque TM, Singh KV, Murray BE.
    Antimicrob Agents Chemother; 1999 Apr; 43(4):930-6. PubMed ID: 10103202
    [Abstract] [Full Text] [Related]

  • 18. In vitro activity of teichomycin compared with those of other antibiotics.
    Neu HC, Labthavikul P.
    Antimicrob Agents Chemother; 1983 Sep; 24(3):425-8. PubMed ID: 6227282
    [Abstract] [Full Text] [Related]

  • 19. In-vitro activity of LY146032 against gram-positive isolates from cancer patients.
    Saito H, Rolston KV, Ho DH, LeBlanc B, Bodey GP.
    J Antimicrob Chemother; 1987 Oct; 20(4):497-503. PubMed ID: 2824425
    [Abstract] [Full Text] [Related]

  • 20. Ex vivo study of serum bactericidal titers and killing rates of daptomycin (LY146032) combined or not combined with amikacin compared with those of vancomycin.
    Van der Auwera P.
    Antimicrob Agents Chemother; 1989 Oct; 33(10):1783-90. PubMed ID: 2556079
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.